Oritavancin
From Wikipedia, the free encyclopedia
 |
|
|
Oritavancin
|
|
| Systematic (IUPAC) name | |
| ? | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | ? |
| Chemical data | |
| Formula | C86H97Cl3N10O26 |
| Mol. mass | 1793.1 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Oritavancin (INN, also known as LY333328) is an investigational glycopeptide antibiotic with bactericidal activity effective in treating infections caused by Gram-positive organisms. It treats complicated skin and skin structure infections. This new drug will be tested for treatment of bacteraemia and nosocomial pneumonia. It demonstrates similar activity to vancomycin, but it has stronger activity against Staphylococcus and Enterococcus. The pharmacokinetics and pharmacodynamics of oritavancin appear to be favourable and once-daily dosing is likely. The incidence of multi-drug resistant bacteria is increasing and explorations into additional treatment options are essential. The clinical efficacy of oritavancin has not yet been determined.
[edit] References
- Ward K, Mersfelder T, LaPlante K (2006). "Oritavancin--an investigational glycopeptide antibiotic". Expert Opin Investig Drugs 15 (4): 417–29. PMID 16548791.
 |
This antibiotic-related article is a stub. You can help Wikipedia by expanding it. |
